AstraZeneca plans to spend $535M-plus to expand its R&D network and manufacturing ops in France
UK-based AstraZeneca is steering a significant amount of R&D and manufacturing spending to France,
On the Monday holiday, the pharma giant made a splash with its French release outlining plans by CEO Pascal Soriot — a native of France — to invest $275 million in additional R&D partnering with its growing network of French biotech and research groups. In particular, AstraZeneca execs want to amp up their work involving French researchers in their global clinical trial network.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.